Ofloxacin monotherapy for the primary treatment of microbial keratitis - A double-masked, randomized, controlled trial with conventional dual therapy

被引:0
|
作者
Pavesio, C
Morlet, N
Allan, B
ElKassaby, H
DeCock, R
Butcher, J
Baer, R
Broadway, D
Charles, SJ
Duguid, G
Heyworth, P
Jenkins, C
Larkin, G
Lloyd, IC
McNaught, A
Dart, J
Tullo, A
Ficker, L
Minassian, D
Matheson, M
Johnson, AP
机构
关键词
D O I
暂无
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background: Ofloxacin is a potent broad-spectrum fluoroquinolone antibiotic commercially available as a topical ophthalmic preparation. The authors compared ofloxacin (0.3%) as a single therapy with their conventional dual therapy of specially prepared, fortified gentamicin (1.5%) and cefuroxime (5.0%) drops for the treatment of suspected microbial keratitis. Methods: The authors enrolled 122 patients with a clinical diagnosis of microbial keratitis in a prospective, randomized, controlled, double-masked study to compare the two therapies. The ofloxacin drops were decanted into identical-looking bottles to the conventional treatment and dispensed with a second bottle containing saline only. The initial and subsequent assessments noted any risk factors, the size and location of the ulcer, and any evidence of corneal and conjunctival toxicity. All ulcers were scraped for microbiologic culture, and isolated organisms were tested for sensitivity to the trial antibiotics. For statistical analysis, a ''cure'' was defined as complete healing of the ulcer (no epithelial defect). A ratio of the two outcome proportions and its confidence limits was used to compare the two treatment groups. Multiple regression analysis using Poisson models was used to adjust for confounding factors that may have modified the outcome ratios. Results: There was no difference in the treatment success between the two treatments, with 67.9% of the conventional treatment group and 62.1% of the ofloxacin group being cured within 14 days (ratio, 1.09; [95% confidence interval, 0.83-1.43]; P = 0.59). However, there was significantly more toxicity encountered with the conventional treatment group (50.8% vs. 10.2%; ratio, 5.00 [95% confidence interval, 2.25-11.11]; P < 0.0001). Poisson regression with adjustment for confounders did not materially change the ratio proportions for either treatment success or toxicity, There was at least a 90% chance to detect a 30% difference between the groups. Conclusions: The authors found that the treatment outcomes with ofloxacin monotherapy compared favorably with their conventional therapy and were associated with less toxicity.
引用
收藏
页码:1902 / 1909
页数:8
相关论文
共 50 条
  • [1] Ofloxacin monotherapy for the primary treatment of microbial keratitis
    Pavesio, C
    Morlet, N
    Minassian, D
    Allen, B
    Tullo, A
    Dart, J
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1996, 37 (03) : 4743 - 4743
  • [2] Randomized Double-Masked Placebo-Controlled Trial for the Management of Pythium Keratitis: Combination of Antibiotics Versus Monotherapy
    Tanna, Vishakha
    Bagga, Bhupesh
    Sharma, Savitri
    Ahirwar, Lalit Kishore
    Kate, Anahita
    Mohamed, Ashik
    Joseph, Joveeta
    [J]. CORNEA, 2023, 42 (12) : 1544 - 1550
  • [3] Letter Regarding: Randomized Double-Masked Placebo-Controlled Trial for the Management of Pythium Keratitis: Combination of Antibiotics Versus Monotherapy Reply
    Tanna, Vishakha Dinesh
    [J]. CORNEA, 2023, 42 (12) : E23 - E23
  • [4] Congenital nystagmus: Randomized, controlled, double-masked trial of memantine/gabapentin
    McLean, Rebecca
    Proudlock, Frank
    Thomas, Shery
    Degg, Chris
    Gottlob, Irene
    [J]. ANNALS OF NEUROLOGY, 2007, 61 (02) : 130 - 138
  • [5] Functional Lung Avoidance for Individualized Radiation Therapy: Results of a Double-Masked, Randomized Controlled Trial
    Yaremko, Brian P.
    Capaldi, Dante P., I
    Sheikh, Khadija
    Palma, David A.
    Warner, Andrew
    Dar, A. Rashid
    Yu, Edward
    Rodrigues, George B.
    Louie, Alexander, V
    Landis, Mark
    Sanatani, Michael
    Vincent, Mark D.
    Younus, Jawaid
    Kuruvilla, Sara
    Chen, Jeff Z.
    Erickson, Abigail
    Gaede, Stewart
    Parraga, Grace
    Hoover, Douglas A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 113 (05): : 1072 - 1084
  • [6] A Randomized Controlled Double-Masked Trial of Albuterol Add-on Therapy in Patients With Multiple Sclerosis
    Khoury, Samia J.
    Healy, Brian C.
    Kivisakk, Pia
    Viglietta, Vissia
    Egorova, Svetlana
    Guttmann, Charles R. G.
    Wedgwood, Josiah F.
    Hafler, David A.
    Weiner, Howard L.
    Buckle, Guy
    Cook, Sandra
    Reddy, Susheel
    [J]. ARCHIVES OF NEUROLOGY, 2010, 67 (09) : 1055 - 1061
  • [7] Multivitamin therapy for recurrent aphthous stomatitis A randomized, double-masked, placebo-controlled trial
    Lalla, Rajesh V.
    Choquette, Linda E.
    Feinn, Richard S.
    Zawistowski, Harriet
    Latortue, Marie C.
    Kelly, Edward T.
    Baccaglini, Lorena
    [J]. JOURNAL OF THE AMERICAN DENTAL ASSOCIATION, 2012, 143 (04): : 370 - 376
  • [8] Phase II Randomized, Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis
    Bonini, Stefano
    Lambiase, Alessandro
    Rama, Paolo
    Sinigaglia, Francesco
    Allegretti, Marcello
    Chao, Wendy
    Mantelli, Flavio
    [J]. OPHTHALMOLOGY, 2018, 125 (09) : 1332 - 1343
  • [9] RANDOMIZED DOUBLE-MASKED TRIAL OF SODIUM OXYFERRISCORBONE FOR THE TREATMENT OF GASTRIC-ULCERS
    MEEROFF, JC
    RUBINSTEIN, M
    LUIS, A
    WACIARZ, M
    EGUIA, O
    MEEROFF, M
    [J]. DIGESTIVE DISEASES AND SCIENCES, 1979, 24 (09) : 680 - 683
  • [10] Randomised double-masked placebo-controlled trial of a treatment for congenital nystagmus
    Evans, BJW
    Evans, BV
    Jordahl-Moroz, J
    Nabee, M
    [J]. VISION RESEARCH, 1998, 38 (14) : 2193 - 2202